Regeneron is starting human testing of its experimental antibody cocktail which aims to treat the coronavirus.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and member of the White House Coronavirus Task Force, talked about Regeneron's antibody-drug with TheStreet.
For those who are not aware, REGN-COV2 is described as "an investigational dual antibody cocktail" designed to prevent and treat COVID-19.
Regeneron said that the testing will consist of four study groups: hospitalized COVID-19 patients; non-hospitalized symptomatic COVID-19 patients; uninfected people in groups that are at high risk of exposure--like healthcare workers or first responders; and uninfected people with close exposure to COVID-19 patients.
Regeneron is also conducting placebo trials.
Fauci explains the science behind the Regeneron drug and further explains why more testing is needed before anyone can really weigh in on the antibody cocktail.
"Again, I use that terminology--because it's true--we're cautiously optimistic that the development of monoclonal antibodies by Regeneron, by [Eli] Lilly, by a variety of other companies, would actually get us closer to a good and effective therapy," Fauci said.
You can follow Katherine Ross on Twitter at @byKatherineRoss.
Watch More of the Latest Videos from TheStreet and Jim Cramer
- Jim Cramer: Broadcom Is 'Greatest Value' of Semiconductor Stocks
- Jim Cramer: Advice for Investors Learning About the Stock Market
- TheStreet Explains: What Is Value Versus Growth in Stocks?
- How Magic Johnson Became the Business Icon He Is Today
- C-Suite: Why the Nikola Executive Team Is Taking Salaries of $1